DE69901805D1 - Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin - Google Patents
Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrinInfo
- Publication number
- DE69901805D1 DE69901805D1 DE69901805T DE69901805T DE69901805D1 DE 69901805 D1 DE69901805 D1 DE 69901805D1 DE 69901805 T DE69901805 T DE 69901805T DE 69901805 T DE69901805 T DE 69901805T DE 69901805 D1 DE69901805 D1 DE 69901805D1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical composition
- ezrin
- mutated
- tyrosin
- tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/040,725 US6399584B1 (en) | 1998-03-18 | 1998-03-18 | Pharmaceutical composition containing ezrin mutated on tyrosine 353 |
PCT/EP1999/002054 WO1999047150A2 (en) | 1998-03-18 | 1999-03-18 | A pharmaceutical composition containing ezrin mutated on tyrosine 353 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69901805D1 true DE69901805D1 (de) | 2002-07-18 |
DE69901805T2 DE69901805T2 (de) | 2003-03-06 |
Family
ID=21912598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69901805T Expired - Fee Related DE69901805T2 (de) | 1998-03-18 | 1999-03-18 | Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin |
Country Status (6)
Country | Link |
---|---|
US (2) | US6399584B1 (de) |
EP (1) | EP1061941B1 (de) |
AT (1) | ATE218881T1 (de) |
AU (1) | AU3600199A (de) |
DE (1) | DE69901805T2 (de) |
WO (1) | WO1999047150A2 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2354241A (en) * | 1999-09-17 | 2001-03-21 | Rupert Donald Holms | Regulatory/unfolding peptides of ezrin |
CA2446458A1 (en) | 2001-05-09 | 2002-11-14 | Yale University | Toll/interleukin-1 receptor adaptor protein (tirap) |
WO2004016739A2 (en) * | 2002-08-01 | 2004-02-26 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Cell modulation using a cytoskeletal protein |
US20070293422A1 (en) * | 2003-04-30 | 2007-12-20 | Applied Research Systems Ars Holding N.V. | Beta-Amyloid Inhibitors and Use Thereof |
WO2005060996A2 (en) * | 2003-12-23 | 2005-07-07 | Lauras As | Method of altering the pka type i signalling pathway |
WO2006036406A2 (en) * | 2004-08-25 | 2006-04-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Live microbial microbicides |
CA2569080A1 (en) * | 2006-11-20 | 2008-05-20 | Institut Pasteur | Anti-coronavirus molecules and their use in compositions and methods for treating and/or preventing infection caused by a coronavirus |
WO2009103312A1 (en) * | 2008-02-19 | 2009-08-27 | Ludwig-Maximilians-Universität | Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases |
EP2480568B1 (de) | 2009-09-23 | 2016-04-20 | Université Paris Descartes | Polypeptide und Nukleinsäuren zur Behandlung von ErbB2-abhängigen Krebserkrankungen |
-
1998
- 1998-03-18 US US09/040,725 patent/US6399584B1/en not_active Expired - Fee Related
-
1999
- 1999-03-18 AT AT99917867T patent/ATE218881T1/de active
- 1999-03-18 WO PCT/EP1999/002054 patent/WO1999047150A2/en active IP Right Grant
- 1999-03-18 DE DE69901805T patent/DE69901805T2/de not_active Expired - Fee Related
- 1999-03-18 EP EP99917867A patent/EP1061941B1/de not_active Expired - Lifetime
- 1999-03-18 AU AU36001/99A patent/AU3600199A/en not_active Abandoned
-
2002
- 2002-04-08 US US10/118,651 patent/US20020115633A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1061941A2 (de) | 2000-12-27 |
ATE218881T1 (de) | 2002-06-15 |
US20020115633A1 (en) | 2002-08-22 |
WO1999047150A3 (en) | 2000-01-20 |
EP1061941B1 (de) | 2002-06-12 |
DE69901805T2 (de) | 2003-03-06 |
US6399584B1 (en) | 2002-06-04 |
AU3600199A (en) | 1999-10-11 |
WO1999047150A9 (en) | 1999-11-18 |
WO1999047150A2 (en) | 1999-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2172654T3 (es) | Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe. | |
BR9708632A (pt) | Composto calcilìticos | |
IS1907B (is) | Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm | |
MD960330A (ro) | Compuşi nepeptidilici, compoziţie farmaceutică pe baza acestora, metodă de tratament | |
AP2001002129A0 (en) | 5HT1 receptor agonists and metoclopramide for the treatment of migrane. | |
BR0307508A (pt) | Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença | |
HK1050860A1 (en) | Nordihydroguaiaretic derivatives for use in treatment of tumors | |
ATE221881T1 (de) | Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat | |
NO20004419L (no) | Ny anvendelse | |
YU13301A (sh) | Muskarinski agonisti i antagonisti | |
TR199800270T1 (xx) | Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�. | |
DE69619052D1 (de) | Feste, wasserfreie, pharmazeutische Zubereitungen für vaginale Verwendung | |
TR200001040T2 (tr) | Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı | |
DK0946157T3 (da) | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte | |
ATE218881T1 (de) | Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin | |
ATE240303T1 (de) | 1,2,4-triazol-3-thion verbindungen | |
ZA947894B (en) | Compounds for medicinal use | |
RS49599B (sr) | Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija | |
TR199802351T2 (xx) | Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi. | |
NO983177L (no) | Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft | |
AU1656997A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
UA48245C2 (uk) | ЗАМІЩЕНІ 1,2,3,4-ТЕТРАГІДРО-2-ДИБЕНЗОФУРАНАМІНИ ТА 2-АМІНОЦИКЛОГЕПТА[B]БЕНЗОФУРАНИ, ФАРМАЦЕВТИЧНА ЛІКАРСЬКА ФОРМА ТА СПОСІБ ПІДВИЩЕННЯ АКТИВАЦІЇ 5-НТ<sub>1F</sub> РЕЦЕПТОРА У ССАВЦЯ | |
ATE500269T1 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
BG104914A (en) | Paroxetine maleate | |
ATE194775T1 (de) | Calcitonin enthaltende pharmazeutische zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |